Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
4 astronauts are en route home from ISS after medical issue forces early exit - 2Grasping the Course of Evacuation and Extradition in U.S. Migration
- 3Kobe Bryant called this WNBA star the 'Gold Mamba.' She turned his advice to her into a tattoo.
- 4Uzbekistan launches €9.46 billion green energy push, covering nation’s power needs
- 5Impact of NIH funding reductions felt in cancer and infectious disease trials
- Figure out What Shift Differentials Mean for Your General Attendant Compensation
- Hot Electric Vehicles for 2023
- How to watch the last supermoon of the year
- The Main 20 Gaming Control center Ever
- 5 Superstar Couples That Motivate Relationship Objectives
- Solid Living Tips: Experiences from a Wellness Fan
- Figure out How to Pick the Right Toothbrush for You
- When fake data is a good thing – how synthetic data trains AI to solve real problems
- Top notch Remote Earphones for Audiophiles
